Browse LRP1

Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Low-density lipoprotein receptor-related protein 1 85 kDa subunit: Cell membrane; Single-pass type I membrane protein. Membrane, coated pit.; SUBCELLULAR LOCATION: Low-density lipoprotein receptor-related protein 1 515 kDa subunit: Cell membrane; Peripheral membrane protein; Extracellular side. Membrane, coated pit.; SUBCELLULAR LOCATION: Low-density lipoprotein receptor-related protein 1 intracellular domain: Cytoplasm. Nucleus. Note=After cleavage, the intracellular domain (LRPICD) is detected both in the cytoplasm and in the nucleus.
Domain PF12662 Complement Clr-like EGF-like
PF16472 Domain of unknown function (DUF5050)
PF07645 Calcium-binding EGF domain
PF00057 Low-density lipoprotein receptor domain class A
PF00058 Low-density lipoprotein receptor repeat class B
Function

Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission (PubMed:11907044, PubMed:12888553, PubMed:12713657). Acts as an alpha-2-macroglobulin receptor (PubMed:26142438). ; FUNCTION: (Microbial infection) Functions as a receptor for Pseudomonas aeruginosa exotoxin A.

> Gene Ontology
 
Biological Process GO:0001523 retinoid metabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0006869 lipid transport
GO:0006898 receptor-mediated endocytosis
GO:0006909 phagocytosis
GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway
GO:0007568 aging
GO:0010517 regulation of phospholipase activity
GO:0010640 regulation of platelet-derived growth factor receptor signaling pathway
GO:0010642 negative regulation of platelet-derived growth factor receptor signaling pathway
GO:0010715 regulation of extracellular matrix disassembly
GO:0010721 negative regulation of cell development
GO:0010874 regulation of cholesterol efflux
GO:0010875 positive regulation of cholesterol efflux
GO:0010876 lipid localization
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014912 negative regulation of smooth muscle cell migration
GO:0015850 organic hydroxy compound transport
GO:0015918 sterol transport
GO:0016055 Wnt signaling pathway
GO:0016101 diterpenoid metabolic process
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021987 cerebral cortex development
GO:0022617 extracellular matrix disassembly
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030198 extracellular matrix organization
GO:0030301 cholesterol transport
GO:0030336 negative regulation of cell migration
GO:0030900 forebrain development
GO:0031345 negative regulation of cell projection organization
GO:0032368 regulation of lipid transport
GO:0032370 positive regulation of lipid transport
GO:0032371 regulation of sterol transport
GO:0032373 positive regulation of sterol transport
GO:0032374 regulation of cholesterol transport
GO:0032376 positive regulation of cholesterol transport
GO:0032429 regulation of phospholipase A2 activity
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033344 cholesterol efflux
GO:0035791 platelet-derived growth factor receptor-beta signaling pathway
GO:0035904 aorta development
GO:0035909 aorta morphogenesis
GO:0040013 negative regulation of locomotion
GO:0042157 lipoprotein metabolic process
GO:0042953 lipoprotein transport
GO:0043062 extracellular structure organization
GO:0043277 apoptotic cell clearance
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0044872 lipoprotein localization
GO:0045665 negative regulation of neuron differentiation
GO:0048008 platelet-derived growth factor receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0048844 artery morphogenesis
GO:0050768 negative regulation of neurogenesis
GO:0051222 positive regulation of protein transport
GO:0051271 negative regulation of cellular component movement
GO:0051402 neuron apoptotic process
GO:0051493 regulation of cytoskeleton organization
GO:0051961 negative regulation of nervous system development
GO:0060191 regulation of lipase activity
GO:0060840 artery development
GO:0070997 neuron death
GO:0097242 beta-amyloid clearance
GO:0198738 cell-cell signaling by wnt
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1903053 regulation of extracellular matrix organization
GO:1904951 positive regulation of establishment of protein localization
GO:2000146 negative regulation of cell motility
GO:2000586 regulation of platelet-derived growth factor receptor-beta signaling pathway
GO:2000587 negative regulation of platelet-derived growth factor receptor-beta signaling pathway
Molecular Function GO:0002020 protease binding
GO:0005041 low-density lipoprotein receptor activity
GO:0030228 lipoprotein particle receptor activity
GO:0034185 apolipoprotein binding
GO:0038024 cargo receptor activity
GO:0042954 lipoprotein transporter activity
GO:0070325 lipoprotein particle receptor binding
Cellular Component GO:0005765 lysosomal membrane
GO:0005905 clathrin-coated pit
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030425 dendrite
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0043025 neuronal cell body
GO:0043235 receptor complex
GO:0044297 cell body
GO:0098589 membrane region
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-1430728: Metabolism
R-HSA-6806667: Metabolism of fat-soluble vitamins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-975634: Retinoid metabolism and transport
R-HSA-2168880: Scavenging of heme from plasma
R-HSA-162582: Signal Transduction
R-HSA-5653656: Vesicle-mediated transport
R-HSA-2187338: Visual phototransduction
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LRP1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24778318Lung Carcinoma; FibrosacromaPromote immunityUsing targeted genetic disruption of the interaction between HSPs and CD91, we demonstrated that specific ablation of CD91 in APCs prevented the establishment of antitumor immunity. The antitumor immunity was also inhibited when the transfer of tumor-derived HSPs to APCs was prevented using an endogenous inhibitor of CD91.
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8090.0145
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3460.533
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4070.778
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2270.58
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4620.899
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0680.988
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.060.918
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.10.961
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0880.971
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4550.811
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4660.582
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3740.00174
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LRP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRP1
Namelow density lipoprotein receptor-related protein 1
Aliases CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ......
Chromosomal Location12q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRP1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LRP1.
ID Name Drug Type Targets #Targets
DB00025Antihemophilic factor, human recombinantBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11
DB00031TenecteplaseBiotechANXA2, CALR, CANX, CLEC3B, FGA, KRT8, LRP1, PLAUR, PLG, SERPINB2, ......11
DB00100Coagulation Factor IX (Recombinant)BiotechF10, F11, F2, F7, F8, GGCX, LRP17
DB06245LanoteplaseBiotechANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......17
DB13152Coagulation Factor IX HumanBiotechF10, F11, F2, F7, F8, GGCX, LRP17
DB13998Lonoctocog alfaBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11
DB13999Moroctocog alfaBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11